Valuation: Galapagos NV

Market Cap 171.33Cr 196.05Cr 158.1Cr 145.73Cr 274.67Cr 19TCr 280.77Cr 1.89TCr 743.26Cr 9.25TCr 736.28Cr 720.13Cr 32TCr P/E 2026 *
-12.2x
P/E 2027 * -9.21x
Enterprise Value -27Cr -31Cr -25Cr -23Cr -43Cr -2.97TCr -44Cr -297.74Cr -117.11Cr -1.46TCr -116.01Cr -113.46Cr -5.02TCr EV / Sales 2026 *
-19x
EV / Sales 2027 * -6.08x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 196.05Cr
+3.90%-0.39%+386.06%+593.85% 3.96TCr
-1.70%+4.46%+5.93%+60.25% 3.47TCr
-2.01%-0.76%+28.41%-8.01% 3.44TCr
+0.06%+0.34%+2.38%+34.38% 2.71TCr
+0.46%-3.49% - - 1.62TCr
-0.04%-0.09%+72.42%+115.55% 1.54TCr
+1.12%+1.91%+14.54%+19.16% 1.41TCr
0.00%+1.36%+18.43%-30.79% 1.3TCr
-0.08%-3.01%+1,282.83%+635.80% 1.18TCr
Average +0.17%+0.04%+226.37%+177.52% 2.29TCr
Weighted average by Cap. +0.24%+0.36%+174.57%+186.15%

Financials

2026 *2027 *
Net sales 1.42Cr 1.63Cr 1.31Cr 1.21Cr 2.28Cr 156.93Cr 2.33Cr 16Cr 6.18Cr 77Cr 6.12Cr 5.99Cr 264.58Cr 4.61Cr 5.27Cr 4.25Cr 3.92Cr 7.39Cr 507.87Cr 7.55Cr 51Cr 20Cr 248.74Cr 20Cr 19Cr 856.27Cr
Net income -81Cr -93Cr -75Cr -69Cr -129.97Cr -8.93TCr -132.85Cr -894.16Cr -351.69Cr -4.38TCr -348.39Cr -340.75Cr -15TCr -24Cr -27Cr -22Cr -20Cr -38Cr -2.62TCr -39Cr -262.28Cr -103.16Cr -1.28TCr -102.19Cr -100Cr -4.42TCr
Net Debt -198.33Cr -226.95Cr -183.01Cr -168.69Cr -317.95Cr -22TCr -325.01Cr -2.19TCr -860.37Cr -11TCr -852.29Cr -833.59Cr -37TCr -199.35Cr -228.12Cr -183.96Cr -169.56Cr -319.6Cr -22TCr -326.69Cr -2.2TCr -864.83Cr -11TCr -856.7Cr -837.91Cr -37TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B